Minimizing immunotherapy’s potentially harmful side effects
MIAMI, FLORIDA (EMBARGOED UNTIL JAN. 4, 2024, at 10 AM EST) – Recent advances in treating multiple myeloma, the second most common blood cancer, and other blood malignancies are providing improved outcomes – and hope – to patients worldwide. But treatment breakthroughs such as the immunotherapy drug teclistamab can lead to potentially lethal side effects, including cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS). These potential side effects have necessitated giving immunotherapy drugs in the hospital setting, where patients remain for five to seven days and receive other drugs ...
Read the release











